Navigation Links
Proposed Settlement Will Make Up to $28 Million Available to Individuals Who Purchased and Companies That Reimbursed for Paxil CR(R)
Date:3/25/2009

WASHINGTON, March 25 /PRNewswire-USNewswire/ -- Persons who purchased or paid for (in whole or in part) Paxil CR(R) and insurance companies and other entities that reimbursed for (in whole or in part) Paxil CR(R) in the United States and its territories may be eligible for relief as part of a $28 million Proposed Settlement. The lawsuit claims that the Paxil CR(R) tablets GlaxoSmithKline ("GSK") manufactured between April 1, 2002 and March 4, 2005 contained a manufacturing defect that caused some of the tablets to split apart. GSK denies all of these claims and any liability.

If approved, the Proposed Settlement will provide up to $28 million to settle the claims in the lawsuit. Some of this money will be paid to insurance companies and other entities that made reimbursements for (in whole or in part) Paxil CR(R) and some of this money will be paid to consumers who purchased or paid for (in whole or in part) Paxil CR(R). The recovery available to insurance companies and other Third-Party Payors ("TPPs") will be based on their number of covered lives as of December 31, 2004. Consumer class members' recovery will be based on the number of Paxil CR(R) tablets that they paid for or purchased, up to $150, that were defective in that they were split before they were removed from the container in which they were purchased.

Potential Class Members do not need to do anything to stay in the class. However, they must submit a Claim Form if they wish to obtain money from the Proposed Settlement. Claim Forms are available by visiting the website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Claim Forms must be postmarked by August 10, 2009.

Class Members wishing to exclude themselves from or object to the Proposed Settlement must do so as outlined in the Notice of Proposed Class Action Settlement, available by visiting the informational website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Those wishing to exclude themselves from the Proposed Settlement must do so no later than May 15, 2009. Those wishing to object to the Proposed Settlement must do so no later than July 1, 2009. A Class Member must remain in the Class in order to object.

The Court has appointed the law firms Strange & Carpenter and Salas & Co., L.C. to represent the proposed Class. The Court will hold a Final Approval Hearing on July 10, 2009. At that time, the Court will consider the motion for attorneys' fees and expenses, and it will decide whether the Proposed Settlement is fair, reasonable and adequate. All potential Class Members are encouraged to visit www.SimonetPaxilCRSettlement.com or call the Simonet Paxil CR(R) Settlement Administrator at 1-866-458-3186 to determine if they are a Class Member and obtain information about their legal rights, how to file a Claim, or how to object or exclude themselves.


'/>"/>
SOURCE Simonet Paxil CR(R) Settlement Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
3. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
4. Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation
5. Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab
6. Screening Proposed for Childhood Cholesterol Levels
7. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
8. Pelosi Statement on Proposed Entitlement Task Force
9. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
10. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
11. AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical ... recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, ... excited to add this excellent dermatology practice to our group’s medical services,” explains ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion ... deck space. Since the lift is mounted on wheels, it can be wheeled out of ... down kit, to fasten to the deck. "We have transformed the feedback from customers into ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology: